Fax: 770-638-1411
- Chest, arm, & jaw pain
- Shortness of breath & rapid breathing
- Rapid or irregular heart palpitations
- Hypertensive urgency
- Fainting, lightheaded & dizziness
- Swelling in legs, ankles, or feet
- Pain or circulation issues in extremities
- Post emergency room discharge
- Urgent care clinic referrals
- Urgent surgical clearance
Currently Enrolling Clinical Trials
We are actively enrolling participants in the clinical trials listed below. These studies are designed to evaluate investigational treatments and advance care for patients. If you or a loved one may be eligible, we encourage you to review the details and speak with our team to learn more about participation.
BalanceD-HF Trial
(AstraZeneca D6402C00012):
A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/dapagliflozin, Compared with Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function.
A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/dapagliflozin, Compared with Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function.
THARROS
(AstraZeneca D5989C00001):
A Randomized, Double-blind, Parallel Group, Multi-center, Phase III Study to Assess the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease.
A Randomized, Double-blind, Parallel Group, Multi-center, Phase III Study to Assess the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease.
TRITON-CM
(Alnylam Pharmaceuticals / ThermoFisher: ALN-TTRSC04-003):
A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Transthyretin-Mediated Amyloidosis with Cardiomyopathy.
A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Transthyretin-Mediated Amyloidosis with Cardiomyopathy.
ICONIC-HF Study
(Pharmacosmos: P-Monofer-CHF-02):
A phase III, randomized, open-label, blinded endpoint, comparative trial of nnferric derisomaltose versus no intravenous (IV) iron on cardiovascular mortality and hospitalizations for worsening heart failure in iron-deficient subjects with symptomatic chronic heart failure (CHF) and reduced left ventricular ejection fraction (LVEF) (≤45 %).
A phase III, randomized, open-label, blinded endpoint, comparative trial of nnferric derisomaltose versus no intravenous (IV) iron on cardiovascular mortality and hospitalizations for worsening heart failure in iron-deficient subjects with symptomatic chronic heart failure (CHF) and reduced left ventricular ejection fraction (LVEF) (≤45 %).
AZURE-CVOT Trial
(AstraZeneca D7960C00015):
Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in High Risk Participants with Atherosclerotic Cardiovascular Disease and Elevated Low-Density Lipoprotein Cholesterol.
Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in High Risk Participants with Atherosclerotic Cardiovascular Disease and Elevated Low-Density Lipoprotein Cholesterol.
LILAC-TIMI 76 Trial
(Anthos Therapeutics / Novartis ANT-010):
Phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of the factor XI inhibitor abelacimab in approximately 1,900 patients with atrial fibrillation (AF) who are considered unsuitable for oral anticoagulation therapy. The primary goal is to assess the effect of abelacimab relative to physician/patient-determined anticoagulation unsuitability on the incidence of ischemic stroke or systemic embolism in this population.
Phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of the factor XI inhibitor abelacimab in approximately 1,900 patients with atrial fibrillation (AF) who are considered unsuitable for oral anticoagulation therapy. The primary goal is to assess the effect of abelacimab relative to physician/patient-determined anticoagulation unsuitability on the incidence of ischemic stroke or systemic embolism in this population.
V-INTERVENTION Trial
(Novartis / Duke Clinical Research Institute (DCRI) CKJX839D1US04R):
Phase IV, double-blind, placebo-controlled clinical trial evaluating inclisiran, a commercially available lipid-lowering therapy, for the prevention of major adverse cardiovascular (MACE) and limb (MALE) events in patients undergoing percutaneous coronary intervention (PCI) or peripheral vascular intervention (PVI). V-INTERVENTION aims to assess the effectiveness of inclisiran versus placebo in reducing the risk of recurrent cardiovascular and limb events by initiating therapy early after successful revascularization procedures.
Phase IV, double-blind, placebo-controlled clinical trial evaluating inclisiran, a commercially available lipid-lowering therapy, for the prevention of major adverse cardiovascular (MACE) and limb (MALE) events in patients undergoing percutaneous coronary intervention (PCI) or peripheral vascular intervention (PVI). V-INTERVENTION aims to assess the effectiveness of inclisiran versus placebo in reducing the risk of recurrent cardiovascular and limb events by initiating therapy early after successful revascularization procedures.
Novartis CDII235A12201 Trial
A multi-center, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate efficacy, safety, and tolerability of DII235 in adults with elevated Lipoprotein(a) and atherosclerotic cardiovascular disease (ASCVD) and/or Type 2 diabetes mellitus.
EASi-PROTKT CVRR
(Boehringer Ingelheim trial # 1378-0041):
Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) (novel specific aldosterone synthase inhibitor (ASi)) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease.
Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) (novel specific aldosterone synthase inhibitor (ASi)) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease.
About Our Research Program and Team
Atlanta Heart Specialists has been advancing cardiovascular research for more than two decades. Our physicians and research staff work alongside national and global partners to study treatments that can improve patient outcomes and prevent future disease.
Our goal is to bring innovative care options to our patients while upholding the highest standards of safety, integrity, and compassion.
David Suh
Director of Research
Hiwat "MiMi" Haile
Lead CRC
Andrew Mayer
CRC
Rigo Villeda
CRC
Sairy "Rachell" Salgado
CRC
Rhonda Hamer-Pirkle
CRC
Soham Jagtap
CRC
.png?width=500&height=555&name=FAQimage3%20(21).png)
FAQs About Clinical Trials
What is a clinical trial?
A clinical trial is a research study that tests new treatments or new ways of using existing treatments. The goal is to see whether they are safe and effective.
Who oversees clinical trials?
All studies follow strict FDA regulations and are approved by an Institutional Review Board (IRB) to ensure patient safety.
What kinds of trials does AHS participate in?
Atlanta Heart Specialists participates in a wide spectrum of multicenter, international cardiovascular clinical trials, including those focusing on primary prevention and those focusing on patients with known cardiovascular disease as well. AHS participates in predominantly Phase 2, 3 and 4 clinical trials - these are studies where treatments have already demonstrated promise in terms of efficacy and safety, resulting in a lower risk for participants.
Are clinical trials safe?
Every study includes close medical supervision. Research participants are monitored carefully, and many find they receive extra attention compared to standard care.
Why should I consider participating?
- Access to new treatments before they are widely available
- Expert care from specialists during the study
- More frequent health check-ins
- Opportunity to help advance medical knowledge and benefit others
Do I have to pay to participate?
No. Participation is free for eligible patients. Any investigational treatments or visits outside standard care are covered, and transportation stipends are available.
What are the risks of clinical trials?
- Some studies may include a placebo (inactive treatment).
- Investigational treatments may have side effects or may not work for you.
- Participation can require extra visits or time.
All potential risks and procedures are explained before you decide to join a study.